Research Article

The Relieving Effects of BrainPower Advanced, a Dietary Supplement, in Older Adults with Subjective Memory Complaints: A Randomized, Double-Blind, Placebo-Controlled Trial

Table 4

(a) Distribution of symptom severity levels (5-point scale) of subjective hypomnesis/memory loss (SML) in older adults before and after BrainPower Advanced or placebo interventions. (b) Ridit scoring test of the ranked data showed that more subjects showed reduced (−) SML symptoms and far fewer subjects showed worsened SML symptoms (+) after BrainPower Advanced intervention than after placebo intervention, . (c) McNemar’s test of the combined data (2 scales: 1-2 and 3–5) of subjective memory loss (SML) shows that BrainPower Advanced intervention, but not placebo intervention, significantly reversed the proportion of severe SML in the older adults. It was noted, however, that BrainPower Advanced group had more severe cases and fewer mild cases of SML than the placebo group before the intervention.
(a)

Distribution of SML symptom severity
Group 1, none or slight2, mild3, moderate4, severe5, very severe

Before interventionBrainPower group0 (0%)3 (6.4%)16 (34.0%)17 (36.2%)11 (23.4%)
Placebo group5 (9.8%)7 (13.7%)7 (13.7%)25 (49.0%)7 (13.7%)
Total5 (5.1%)10 (10.2%)23 (23.5%)42 (42.9%)18 (18.4%)

After interventionBrainPower group2 (4.3%)14 (29.8%)18 (38.3%)11 (23.4%)2 (4.3%)
Placebo group2 (3.9%)12 (23.5%)27 (52.9%)10 (19.6%)0 (0%)
Total 4 (4.1%)26 (26.5%)45 (45.9%)21 (21.4%)2 (2.0%)

(b)

Symptom score change⁢BrainPower group⁢Placebo groupTotal

−324.312.033.1
−21225.51019.62222.4
−12042.61223.53232.7
01225.51529.42727.6
+112.11019.61111.2
+200.023.922.0
+300.012.011.0
Total47100.051.0100.098100.0

(c)

Treatment group Before interventionAfter intervention value of McNemar’s test
No or slightSevereNo or slightSevere

BrainPower group3 (6.4%)44 (93.6%)16 (34.0%)31 (66.0%)0.001
Placebo group12 (23.5%)39 (76.5%)14 (27.5%)37 (72.5%)0.791
Pearson 5.5470.5
0.0190.479